Prognostic Comparison of Octogenarian vs. Non-Octogenarian With Acute Decompensated Heart Failure - AURORA Study

Circ J. 2023 Dec 25;88(1):103-109. doi: 10.1253/circj.CJ-23-0470. Epub 2023 Oct 5.

Abstract

Background: Acute decompensated heart failure (ADHF) is the main cause of hospitalization and death of octogenarians, but no data on the 1-year post-discharge mortality rate. We evaluated the clinical status and predictors of 1-year mortality in octogenarians with ADHF.

Methods and results: From the AURORA (Acute Heart Failure Registry in Osaka Rosai Hospital) study, we examined 1,246 hospitalized ADHF patients. We compared the in-hospital mortality rate and the proportion of heart failure (HF) with preserved ejection fraction (HFpEF) between octogenarians and non-octogenarians. After discharge we compared the 1-year mortality rate between these groups, and we also evaluated the predictors of death in both groups. The proportion of HFpEF among the in-hospital deaths of octogenarians was significantly higher than in non-octogenarians (46.2% vs. 15.0%, P=0.031). The 1-year mortality rate after discharge was significantly higher in the octogenarians than non-octogenarians (P=0.014). Multivariable Cox regression analysis revealed that albumin ≤3.0 g/dL and antiplatelet agents were useful predictors of 1-year death after discharge of octogenarians whereas chronic kidney disease was a predictor in the non-octogenarians.

Conclusions: The proportion of HFpEF among in-hospital deaths of octogenarians with ADHF was high as compared with non-octogenarians. When octogenarians with ADHF have severe hypoalbuminemia and antiplatelet agents, early nutritional and medical interventions after discharge may be important to improve the 1-year prognosis.

Keywords: Acute decompensated heart failure; Albumin; Antiplatelet agents; Octogenarians.

MeSH terms

  • Aftercare
  • Aged, 80 and over
  • Heart Failure*
  • Humans
  • Octogenarians*
  • Patient Discharge
  • Platelet Aggregation Inhibitors
  • Prognosis
  • Risk Factors
  • Stroke Volume

Substances

  • Platelet Aggregation Inhibitors